Asunto(s)
Enfermedades Carenciales/prevención & control , Suplementos Dietéticos , Metabolismo Energético , Inmunidad Innata , Selenio/uso terapéutico , Animales , Cardiomiopatías/etiología , Cardiomiopatías/prevención & control , Enfermedades Carenciales/inmunología , Enfermedades Carenciales/metabolismo , Enfermedades Carenciales/fisiopatología , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/prevención & control , Suplementos Dietéticos/envenenamiento , Infecciones por Enterovirus/etiología , Infecciones por Enterovirus/prevención & control , Humanos , Enfermedad de Kashin-Beck/etiología , Enfermedad de Kashin-Beck/prevención & control , Neoplasias/etiología , Neoplasias/prevención & control , Necesidades Nutricionales , Ingesta Diaria Recomendada , Selenio/deficiencia , Selenio/metabolismo , Selenio/envenenamientoRESUMEN
OBJECTIVE: The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer. METHODS: Thirty-one patients with stage I-III endometrial cancer were recruited for this study. The stage I patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy. RESULTS: The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31). CONCLUSIONS: 252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range.
Asunto(s)
Adenocarcinoma/radioterapia , Braquiterapia/métodos , Californio/uso terapéutico , Neoplasias Endometriales/radioterapia , Adenocarcinoma/mortalidad , Adenocarcinoma/patología , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Braquiterapia/instrumentación , Carmustina/uso terapéutico , Terapia Combinada , Citarabina/uso terapéutico , Neoplasias Endometriales/mortalidad , Neoplasias Endometriales/patología , Femenino , Estudios de Seguimiento , Humanos , Melfalán/uso terapéutico , Persona de Mediana Edad , Podofilotoxina/uso terapéutico , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
OBJECTIVE: The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer. METHODS: Thirty-one patients with stage I-III endometrial cancer were recruited for this study. The stage I patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy. RESULTS: The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31). CONCLUSIONS: 252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range.